Please assess the completion status of the following clinical trial:

Trial Title: Closed-loop Control of Glucose Levels (Artificial Pancreas) for 12 Days in Adults With Type 1 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Males and females ≥ 18 years of old.~2. Clinical diagnosis of type 1 diabetes for at least one year.~3. The subject will have been on insulin pump therapy for at least 3 months.~4. HbA1c ≤ 12%.~Exclusion Criteria:~1. Clinically significant nephropathy, neuropathy or retinopathy as judged by the investigator~2. Recent (\< 6 months) acute macrovascular event e.g. acute coronary syndrome or cardiac surgery~3. Warfarin chronic treatment if INR monitoring cannot be evaluated (can increase the risk of bleeding)~4. Chronic use of acetaminophen. Acetaminophen may interfere with glucose sensor readings~5. Pregnancy (ongoing or current attempt to become pregnant)~6. Breastfeeding~7. No nearby party for assistance if needed~8. Plans to go abroad or travel at more than 2 hours distance from Montreal during the trial period~9. Severe hypoglycemic episode within two weeks of screening or during the run-in period~10. Severe hyperglycemic episode requiring hospitalization in the last 3 months~11. Current use of glucocorticoid medication (except low stable dose and inhaled steroids)~12. Known or suspected allergy to the trial products~13. Other serious medical illness likely to interfere with study participation or with the ability to complete the trial by the judgment of the investigator~14. Anticipation of a significant change in exercise regimen between admission and end of the trial (i.e. starting or stopping an organized sport)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sensor-augmented pump therapy (Type: ACTIVE_COMPARATOR): Participants will use sensor-augmented pump therapy with low-glucose suspend to regulate glucose levels. The low-glucose suspend feature available in the MiniMed® Paradigm® Veo™, Medtronic combined with the Enlite sensor® will be used. This feature allows for suspension of insulin delivery at a pre-set sensor glucose value for up to 2 hours.
- Single-hormone closed-loop strategy (Type: ACTIVE_COMPARATOR): Variable subcutaneous insulin infusion will be used to regulate glucose levels. Participant's usual fast-acting insulin analog will be infused using a subcutaneous infusion pump (MiniMed® Paradigm® Veo™, Medtronic). Every 10 minutes, the glucose levels as measured by the sensor (Enlite sensor®, Medtronic) will be transferred automatically to a smartphone, that harbors the algorithm, that will calculate the recommended doses and will send it wirelessly to the infusion pump.

Based on this trial design, predict the completion outcome and termination type (if applicable).